cbdMD stock analysis
Want to see YCBD full AI Analyst Report?
cbdMD (YCBD) Stock Price & Analysis
YCBD Stock Chart & Stats
- Day’s Range
- $0.34 - $0.37
- 52-Week Range
- $0.33 - $2.56
- Previous Close
- $0.37
- Volume
- N/A
- Average Volume (3M)
- 147.29K
- Market Cap
- $4.19M
- Enterprise Value
- $7.24M
- Total Cash (Recent Filing)
- $2.12M
- Total Debt (Recent Filing)
- $2.21M
- Price to Earnings (P/E)
- ―
- Beta
- 1.35
- Next Earnings
- Dec 18, 2026 (Est.)
- EPS Estimate
- -0.09
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Wholesale Growth
Strong quarterly and year-to-date sales growth, together with faster wholesale expansion, indicates improving distribution and customer reach. A larger wholesale contribution can broaden revenue sources and provide a more scalable foundation for growth over the coming quarters.
Cost Reduction Program
The implemented rightsizing program provides a defined path to reduce recurring cash expenses through payroll, lease, vendor, and supply-chain actions. If realized, these savings could lower cash burn, improve adjusted EBITDA, and move the company closer to breakeven.
Diversification Through Twinlab Acquisition
Adding Twinlab, Reserveage, Metabolife, and ResVitale expands cbdMD beyond hemp-derived products into established wellness categories. This broader portfolio can diversify revenue, improve channel reach, and reduce exposure to a single regulatory framework.
Bears Say
Persistent Losses And Cash Burn
Deeply negative operating and free cash flow show that the business is not currently self-funding its operations. Continued cash burn can constrain investment capacity and increase reliance on financing or balance-sheet resources until profitability becomes consistent.
Margin Compression And Operating Losses
Lower gross margins combined with a wider operating loss indicate that revenue growth is not yet translating proportionally into profitability. Wholesale mix, regulatory rework, and higher expenses may continue to limit earnings conversion while the company scales.
Hemp Regulatory Exposure
Potential changes to the federal hemp definition and THC limits could affect parts of cbdMD’s existing product portfolio and distribution model. Uncertain timing and outcomes make compliance costs, product eligibility, and revenue continuity difficult to plan.
cbdMD News
cbdMD’s Bluebird Botanicals announces official partnership with Denver Audubon
cbdMD (YCBD) through its Bluebird Botanicals brand announced an official partnership with Denver Audubon, a Colorado-based conservation organization. “Bluebird has always stood for more than products,” said Ronan Kennedy, CEO
Analyst Reiterates Buy on cbdMD, Maintains $2 Price Target Amid Solid Revenue Momentum and Strategic Expansion
Anthony Vendetti, an analyst from Maxim Group, maintained the Buy rating on cbdMD. The associated price target remains the same with $2.00. Anthony Vendetti has given his Buy rating due
YCBD FAQ
What was cbdMD’s price range in the past 12 months?
What is cbdMD’s market cap?
When is cbdMD’s upcoming earnings report date?
How were cbdMD’s earnings last quarter?
Is cbdMD overvalued?
Does cbdMD pay dividends?
What is cbdMD’s EPS estimate?
How many shares outstanding does cbdMD have?
What happened to cbdMD’s price movement after its last earnings report?
Which hedge fund is a major shareholder of cbdMD?
What is the TipRanks Smart Score and how is it calculated?
Company Description
cbdMD
cbdMD, Inc. is engaged in the production and distribution of a diverse array of cannabidiol (CBD) products. The company oversees and markets several consumer-oriented, hemp-derived CBD brands, notably its primary brand cbdMD, alongside Paw CBD and cbdMD Botanicals. Under the cbdMD label, its offerings span various items, including CBD tinctures, edible gummies, topical applications, capsules, bath bombs, bath salts, and solutions designed to aid sleep. Furthermore, its Paw CBD brand caters to pets with veterinarian-formulated products such as tinctures, edible chews, and topical treatments. The company's merchandise reaches customers throughout the United States via its proprietary e-commerce platform, various third-party online retail sites, wholesale partners, and physical brick-and-mortar establishments. cbdMD, Inc. also maintains a research collaboration with the University of Mississippi, focusing on the discovery of novel cannabinoids. Incorporated in 2015, the firm was previously known as Level Brands, Inc. before officially changing its name to cbdMD, Inc. in May 2019, and its corporate headquarters are situated in Charlotte, North Carolina.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- T. Ronan Kennedy
- Employees
- 42
- Website
- www.cbdmd.com
- Address
- 2101 Westinghouse Blvd, Charlotte, NC, 28273, US
cbdMD (YCBD) Earnings & Revenues
YCBD Company Deck
YCBD Earnings Call
Earnings Call SentimentNeutral
The call presented balanced progress: clear top-line growth drivers (20% quarterly revenue growth, 61% wholesale growth, Oasis momentum, >$0.5M from Bluebird) and operational actions (cost reductions, product launches) that position the company to navigate near-term uncertainty. However, margin compression (gross margin down ~570 bps YoY in the quarter), higher operating losses and working capital build, inventory reserves, state-level restrictions, and material regulatory uncertainty are significant headwinds. Management emphasized deliberate investments and a path to improved adjusted EBITDA and lower cash burn, but tangible risks remain until regulatory clarity and cost savings are fully realized.
View all YCBD earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 15 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 0 | 0 | 12 |













